#United States #New York #Life Sciences #Clarivate #Altaris

Clarivate Completes Strategic Sale of Life Sciences & Healthcare Division

Clarivate Plc, a prominent global intelligence provider, has made headlines by announcing the sale of its Life Sciences & Healthcare (LSH) segment to Altaris LLC for a staggering $600 million. This strategic move is aimed at honing the company’s focus on its subscription-driven business model, enhancing their offerings in the Academia, Government, and Intellectual Property segments.

Key Insights into the Transaction

The sale is expected to reshape Clarivate's operational structure, allowing for improved revenue dynamics and a refined Adjusted EBITDA margin. As part of the agreement, the company will receive an initial cash payment of $500 million upon closing, with additional deferred payments and a seller note totaling $75 million, reinforcing their financial stability.

Matti Shem Tov, CEO of Clarivate, expressed optimism over the agreement, stating that it aligns perfectly with the company's broader strategy for value creation and optimization of their business model. By divesting the LSH segment, Clarivate anticipates enhanced operational efficiency and a stronger portfolio focused squarely on the knowledge and innovation economy.

Strengthening the Financial Position

Jonathan Collins, CFO of Clarivate, highlighted that this divestiture not only simplifies the company's operations but also propels its debt reduction initiatives. The transition is expected to augment revenue quality, lower capital intensity, and ultimately result in a streamlined organization with increased financial flexibility.

The LSH segment has been an integral part of Clarivate, offering vital insights and analytical capabilities throughout the drug and device lifecycle. Henry Levy, President of the LSH segment, noted the strong foundations established within the segment and expressed confidence that under Altaris, it can embark on a new growth trajectory.

Future Outlook and Financial Guidance

Clarivate's decision to sell its LSH segment has not altered its expectations for the financial year 2026. The company has reaffirmed its revenue and adjusted EBITDA forecasts, keeping its eyes set on long-term growth objectives. The impact of this divestiture will be reflected in their financial outlook starting from the third quarter, as results from the LSH segment will be categorized as discontinued operations.

While a non-cash goodwill impairment of approximately $225 to $250 million on the LSH segment will be recorded based on the sale's terms, it will not influence the overall financial metrics for the year. Clarivate continues to emphasize its revenue growth for 2026, predicting revenues ranging between $2.30 billion to $2.42 billion, alongside maintaining a robust free cash flow forecast.

Conclusion

With a clear trajectory established post-sale, Clarivate is strategically positioning itself to harness its core capabilities better, primarily focusing on advancing its Academia, Government, and Intellectual Property business segments. The divestiture is expected to catalyze significant value creation for all stakeholders, reflecting a robust commitment to optimizing operations and driving sustained growth into the future.

The transaction is projected to close by the year-end, contingent upon a variety of customary conditions, including regulatory approvals. Clarivate remains committed to communicating transparently with stakeholders throughout this transformative journey.